204.53MMarket Cap-26082P/E (TTM)
2.630High2.530Low959Volume2.630Open2.507Pre Close2.44KTurnover0.00%Turnover RatioLossP/E (Static)80.84MShares3.57052wk High3.66P/B137.50MFloat Cap1.81052wk Low--Dividend TTM54.35MShs Float11.950Historical High--Div YieldTTM3.99%Amplitude1.810Historical Low2.546Avg Price1Lot Size
Innate Pharma Stock Forum
NEWS
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...
NEWS
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
🔸Promising preclinical data for IPH4...
NEWS
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement.
The ANKET is Innate's platform for developing multi-specific natural killer...
No comment yet